Healthcare & Life Sciences

Symphogen

Denmark

series-c-plus

Stage

Investors

About

Symphogen develops antibody-based therapies using proprietary antibody mixture technology aimed at treating cancer and other diseases by creating synergistic therapeutic effects.

Explore Symphogen's full profile on Brouky

Funding rounds, investor list, and risk signals — unlock with a subscription.